We are live on ! Find out more
ICM

Invenomic Capital Management Portfolio holdings

AUM $2.18B
1-Year Est. Return 0.03%
This Fund
S&P 500
This Quarter Est. Return
-9.67%
1 Year Est. Return
+0.03%
3 Year Est. Return
-6.37%
5 Year Est. Return
-25.27%
10 Year Est. Return
–
AUM
$2.05B
AUM Growth
+$174M
Cap. Flow
+$354M
Cap. Flow %
17.24%
Top 10 Hldgs %
26.45%
Holding
190
New
45
Increased
56
Reduced
57
Closed
32

Top Buys

Rank Stock Value
1
SOLV icon
Solventum
SOLV
+$50M
2
GPN icon
Global Payments
GPN
+$29.6M
3
APTV icon
Aptiv
APTV
+$29.1M
4
COUR icon
Coursera
COUR
+$23.9M
5
NEM icon
Newmont
NEM
+$23.2M

Top Sells

Rank Stock Value
1
MMM icon
3M
MMM
+$38.8M
2
ADM icon
Archer Daniels Midland
ADM
+$37.9M
3
CAG icon
Conagra Brands
CAG
+$25.2M
4
WEX icon
WEX
WEX
+$23M
5
SMAR
Smartsheet Inc.
SMAR
+$21.9M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 16.97%
2 Technology 15.71%
3 Healthcare 12.23%
4 Communication Services 9.72%
5 Energy 9.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBRG
151
DELISTED
TruBridge
TBRG
$1.46M 0.07%
145,849
-2,930
-2% -$26.7K
REZI icon
152
Resideo Technologies
REZI
$3.95B
$1.44M 0.07%
+73,588
New +$1.52M
LEXX icon
153
Lexaria Bioscience
LEXX
$8.71M
$1.43M 0.07%
34,238
+2,687
+9% +$121K
XERS icon
154
Xeris Biopharma Holdings
XERS
$1.45B
$1.33M 0.06%
592,078
-12,434
-2% -$25.1K
NAK
155
Northern Dynasty Minerals
NAK
$958M
$886K 0.04%
2,851,962
-26,585
-0.9% -$7.99K
PETS icon
156
PetMed Express
PETS
$42.3M
$834K 0.04%
205,985
-4,244
-2% -$18.1K
LASR icon
157
nLIGHT
LASR
$3.17B
$628K 0.03%
57,481
-31,869
-36% -$388K
NGVT icon
158
Ingevity
NGVT
$2.68B
$577K 0.03%
13,202
-31,245
-70% -$1.51M
ABM icon
159
ABM Industries
ABM
$2.84B
– –
-225,695
Closed -$10.1M
ADM icon
160
Archer Daniels Midland
ADM
$36.9B
– –
-603,681
Closed -$37.9M
ADT icon
161
ADT
ADT
$5.58B
– –
-411,522
Closed -$2.77M
AEE icon
162
Ameren
AEE
$30.1B
– –
-194,200
Closed -$14.4M
ALE
163
DELISTED
Allete
ALE
– –
-250,895
Closed -$15M
AVB icon
164
AvalonBay Communities
AVB
$26.8B
– –
-25,603
Closed -$4.75M
BG icon
165
Bunge Global
BG
$20.8B
– –
-119,932
Closed -$12.3M
CAG icon
166
Conagra Brands
CAG
$7.23B
– –
-848,595
Closed -$25.2M
CSTE icon
167
Caesarstone
CSTE
$79.5M
– –
-36,046
Closed -$147K
CSTL icon
168
Castle Biosciences
CSTL
$979M
– –
-166,714
Closed -$3.69M
CVEO icon
169
Civeo
CVEO
$318M
– –
-20,458
Closed -$549K
CVS icon
170
CVS Health
CVS
$122B
– –
-189,996
Closed -$15.2M
DSP icon
171
Viant Technology
DSP
$265M
– –
-52,589
Closed -$561K
HCSG icon
172
Healthcare Services Group
HCSG
$1.53B
– –
-484,237
Closed -$6.04M
LRN icon
173
Stride
LRN
$3.43B
– –
-67,739
Closed -$4.27M
LXFR icon
174
Luxfer Holdings
LXFR
$458M
– –
-274,003
Closed -$2.84M
LYEL icon
175
Lyell Immunopharma
LYEL
$360M
– –
-43,576
Closed -$1.94M
4 5 6
7
8

Similar funds

SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
ORCP
One Rock Capital Partners New York $2.19B AUM
ET
Entropy Technologies New York $2.17B AUM 21.46% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
MIAS
Mason Investment Advisory Services Reston, Virginia $2.17B AUM 28.39% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
IIP
Intermede Investment Partners London, United Kingdom $2.16B AUM 18.47% 1-Year Est. Return

Invenomic Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Invenomic Capital Management held 190 positions worth $2.05B, up 9.3% from $1.88B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Invenomic Capital Management deployed $354M of net new capital in Q2 2024, opening 45 new positions and adding to 56 existing holdings. Its largest new stake was Solventum: 824,185 shares worth $43.6M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was 3M, an estimated $38.8M trimmed.

  • Invenomic Capital Management's largest Q2 2024 buy was Solventum: 824,185 shares worth $43.6M.
  • Invenomic Capital Management added most to Global Payments in Q2 2024, an estimated $29.6M increase.
  • Invenomic Capital Management's biggest Q2 2024 reduction was 3M, cutting an estimated $38.8M.
  • Invenomic Capital Management fully exited Archer Daniels Midland in Q2 2024, selling an estimated $37.9M.
  • Invenomic Capital Management's ten largest holdings make up 26% of its $2.05B portfolio in Q2 2024.
  • Invenomic Capital Management opened 45 new positions and closed 32 in Q2 2024.
  • Invenomic Capital Management's portfolio value rose 9.3% quarter-over-quarter to $2.05B.

Based on Invenomic Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.